Menu
VividWhite’s lead medical device in human clinical trials is a microfluidic surgical implant that carries fluid from the front of the eye, to disperse in the surrounding tissue to relieve intra-ocular pressure and treat glaucoma. As part of the company’s portfolio, VividWhite is developing a world first diagnostic system to clinically and intra-operatively assess eye tissue functionality.
Computational modeling of fluid flow and IOP, animal research, design and develop VW-1 and VW-2 prototypes.
Company formation, private investment, design and develop VW-3 then VW-4 devices. Preclinical assessment of VW-4.
Nanofabrication techniques finalised to create VW-5 series, clinical grade devices ready for human use. Patent filing.
Human clinical study in 10 patients initiated to assess device safety and performance.
Larger scale 65+ human multi-centre clinical study for device registration.
BSc MCom
Experienced MedTech CEO and has established, managed and raised capital for private and ASX listed companies, developing and commercialising novel medical devices and biotech for international markets.
MBBS, FRANZCO, GAICD
Experienced MedTech CEO and has established, managed and raised capital for private and ASX listed companies, developing and commercialising novel medical devices and biotech for international markets.
BSc MEng
Biomedical Engineer experienced working with start-ups, SMEs and universities to design and develop medical devices, project managed several device development programs through to pre-clinical and human trials.
MBBS
Medical practitioner and ophthalmology researcher, with experience managing in-vivo laboratory studies and human clinical studies with a Clinical Research Organisation (CRO).
BSc MEng
Biomedical Engineer with skills in microfluidic technologies, product design and project management. Experienced working in a startup environment and has participated in university and SME accelerator programs.
VividWhite brings together world leaders in ophthalmology, microfluidics, nano/micro fabrication, medical device commercialisation.
VividFlo is a micro-sized, leaf shaped, medical device containing an internal network of channels to drain fluid out of the eye to relieve intra-ocular pressure, treat glaucoma and prevent permanent vision loss.
VividFlo is surgically implanted under the eyelid and allows fluid to travel from the front of the eye through the micro fluid channels about half the thickness of a human hair before gently perfusing out 150+ exit channels to the surrounding tissues. Other novel and patented features prevent leakage and hypotony (deflation of the eye).
VividFlo has been designed to improve the long-term performance of glaucoma drainage devices, by maintaining a high level of tissue permeability.
VividLab is a surgical instrument used during ophthalmic surgery to characterise the condition of the ocular tissue in patients with an elevated IOP and/or glaucoma, as a diagnostic aid. VividLab is also used to stabilise the intraocular pressure at safe levels (and prevent hypotony) in patients undergoing intraocular surgery.
This device will assist ophthalmic surgeons to understand the drainage capacity and permeability of the eye’s trabecular network to predict the outflow functionality or the tissue’s Effective Ocular Porosity (EOP).
Glaucoma is the most common cause of preventable blindness and affects more than 300,000 Australians1 and 60.5 million people worldwide2, with the World Health Organisation estimating that 4.5 million people are living with blindness as a result of glaucoma3.
Some problems are so complex that you have to be highly intelligent and well
informed just to be undecided about them.
Existing management strategies for glaucoma rely on a reduction in the intra-ocular pressure (IOP) of the eye – “the only treatable risk factor that has been identified to delay progression of glaucoma”4.
Glaucoma surgery is the most effective means for lowering intraocular pressure by providing a new route for fluid to exit the eye. This new pathway is through the sclera of the eye into sub-conjunctival tissue, where a fluid filled bleb typically forms under the conjunctiva. The long-term success of the procedure relies on the capacity of the sub-conjunctival tissue to absorb the excess fluid presented to it, without generating excessive scar tissue during tissue remodeling that will shut-down fluid flow. 1
Need more information? Provide us with your details and we will contact you as soon as possible. Alternatively, send us an email at contact@vividwhite.com.au
1) Gardiner BS, Smith DW, Coote M, Crowston JG. Computational modeling of fluid flow and intra-ocular pressure following glaucoma surgery. PLoS One. 2010 Oct 4;5(10):e13178. doi: 10.1371/journal.pone.0013178. PMID: 20957178; PMCID: PMC2949396. https://pubmed.ncbi.nlm.nih.gov/20957178/
2) Nguyen DQ, Ross CM, Li YQ, Pandav S, Gardiner B, Smith D, How AC, Crowston JG, Coote MA. A model to measure fluid outflow in rabbit capsules post glaucoma implant surgery. Invest Ophthalmol Vis Sci. 2012 Oct 5;53(11):6914-9. doi: 10.1167/iovs.12-10438. PMID: 22956615. https://pubmed.ncbi.nlm.nih.gov/22956615/
3) Coote M. Stenting eyes: the pressure to perform. Clin Exp Ophthalmol. 2013 Sep-Oct;41(7):631-2. doi: 10.1111/ceo.12177. PMID: 24090411. https://pubmed.ncbi.nlm.nih.gov/24090411/
4) Ross C, Pandav SS, Li YQ, Nguyen DQ, Beirne S, Wallace GG, Shaarawy T, Crowston JG, Coote M. Determination of bleb capsule porosity with an experimental glaucoma drainage device and measurement system. JAMA Ophthalmol. 2015 May;133(5):549-54. doi: 10.1001/jamaophthalmol.2015.30. PMID: 25719729. https://pubmed.ncbi.nlm.nih.gov/25719729/
5) Pandav SS, Ross CM, Thattaruthody F, Nada R, Singh N, Gautam N, Beirne S, Wallace GG, Sherwood MB, Crowston JG, Coote M. Porosity of Bleb Capsule declines rapidly with Fluid Challenge. J Curr Glaucoma Pract. 2016 Sep-Dec;10(3):91-96. doi: 10.5005/jp-journals-10008-1208. Epub 2016 Oct 29. PMID: 27857488; PMCID: PMC5104968. https://pubmed.ncbi.nlm.nih.gov/27857488/
6) Coote M. Blebs, Barriers, and Bagpipes: Why is it so Hard? J Curr Glaucoma Pract 2016; 10(3):79-84. https://pubmed.ncbi.nlm.nih.gov/27857486/
Please enter your Username and Password to access our secure information area.